Cell & Gene Manufacturing Process Efficiencies: Best Practice Guide
The level of process efficiency behind today’s cell and gene therapies is said to rest at a low. The manufacturing behind them is mostly manual, due to the treatments mostly being within early development stages. There are, however, some cases where companies utilise partly automated solutions.
Pharma IQ spoke with Elena Meurer, Head of Pharmaceutical and Technical Development at apceth GmbH & Co.KG about the progress required behind this market in regards to process excellence Download this piece to learn more about:
- The level of process efficiency behind today’s cell and gene therapies
- The two major routes towards improvement Elena Meurer sees for the future
- The greatest challenges for the market
Please note: That all fields marked with an asterisk (*) are required.